Article

Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer’s disease

2023-05-22

Abstract excerpt

Recent genome-wide association studies have revealed genetic risk factors for Alzheimer’s disease (AD) that are exclusively expressed in microglia within the brain. A proteomics approach identified moesin (MSN), a FERM (four-point-one ezrin radixin moesin) domain protein, and the receptor CD44 as hub proteins found within a co-expression module strongly linked to AD clinical and pathological traits as well as micr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c1971e7d-cc49-5658-85c1-b5efab11bb7c
DOI: 10.1101/2023.05.22.541727

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer’s diseaseDOI 10.1101/2023.05.22.541727Read

Structure of the FERM domain of a neural scaffold protein FRMPD4 implicated in X-linked intellectual disability.Semantic proximity Read

Conformational flexibility determines the Nf2/merlin tumor suppressor functionsSemantic proximity Read

Protein 4.1 tumor suppressors: getting a FERM grip on growth regulationSemantic proximity Read

XL-MS and De Novo Protein Design Identified a Common Motif for TREM2 BindingSemantic proximity Read

The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene productSemantic proximity Read

The expanding family of FERM proteinsSemantic proximity Read

Drug screening targeting TREM2-TYROBP transmembrane bindingSemantic proximity Read

Activation of moesin, a protein that links actin cytoskeleton to the plasma membrane, occurs by phosphatidylinositol 4,5-bisphosphate (PIP2) binding sequentially to two sites and releasing an autoinhibitory linker.Semantic proximity Read

TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional CharacterizationSemantic proximity Read

AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial ActivitySemantic proximity Read

Aβ-Overlapping Ectodomain Binding of the Clinical-Stage TREM2 Agonist VG-3927Semantic proximity Read